Boehringer Ingelheim GmbH
http://www.boehringer-ingelheim.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Boehringer Ingelheim GmbH
Progress In Pharma’s Slow Battle Against A Deadly Infant Virus
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.
Coronavirus Notebook: A UK Catapult, A Russian Vaccine, And A Cuban Therapy
The UK BioIndustry Association has welcomed the government’s fresh investment in COVID-19 vaccine manufacturing capacity, while Sanofi and GSK are striking European and US deals for their vaccine candidate. A number of potential therapies are also being developed, including products based on interferon and hyperimmune globulin, but Roche/Chugai’s Actemra (tocilizumab) looks like a non-runner.
August User Fee Calendar Features Gene Therapy, Analgesics, And Of Course Oncology
Sixteen applications are in line for US FDA decisions in August. Ten are novel agents.
Lilly Points To Six-Month Growth Instead Of Pandemic Impacted Q2
Lilly argues the overall trend is positive, although the second quarter was down. Trial successes with Verzenio, Trulicity, Jardiance and mirikizumab offer additional growth potential.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- AMAL Therapeutics SA
- ICD Therapeutics
- SSP Co., Ltd.
- Vira Therapeutics GmbH (Vira T)